Literature DB >> 8884861

Complement activation during and after open-heart surgery is only marginally affected by the choice of fluid for volume replacement.

J L Svennevig1, S Tølløfsrud, U Kongsgaard, H Noddeland, B Mohr, M Ozer, T E Mollnes.   

Abstract

Forty patients undergoing CPB for coronary artery surgery, using a standardized technical setting, were randomized to receive either Ringer's acetate, dextran 70 (Macrodex), polygeline (Haemaccel) or albumin 4% for volume replacement during and after surgery. The choice of fluid did not affect early complement activation (C3 activation products). Higher values of the terminal complement complex (TCC) were found only at the end of the operation in patients receiving polygeline. There were no differences between any two of the four groups during the postoperative course. The use of blood transfusion or autotransfusion and the degree of haemodilution and hypothermia did not affect complement activation. We conclude that complement activation in association with open-heart surgery is only marginally affected by the choice of fluid for volume replacement.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8884861     DOI: 10.1177/026765919601100405

Source DB:  PubMed          Journal:  Perfusion        ISSN: 0267-6591            Impact factor:   1.972


  3 in total

Review 1.  Human albumin solution for resuscitation and volume expansion in critically ill patients.

Authors:  Ian Roberts; Karen Blackhall; Phil Alderson; Frances Bunn; Gillian Schierhout
Journal:  Cochrane Database Syst Rev       Date:  2011-11-09

Review 2.  Colloid solutions for fluid resuscitation.

Authors:  Frances Bunn; Daksha Trivedi
Journal:  Cochrane Database Syst Rev       Date:  2012-07-11

3.  Universal fresh frozen plasma (Uniplas): a safe product in open-heart surgery.

Authors:  Stein Tølløfsrud; Harald Noddeland; Jan Ludvig Svennevig; Gunnar Bentsen; Tom Eirik Mollnes; Bjarte G Solheim
Journal:  Intensive Care Med       Date:  2003-09-04       Impact factor: 17.440

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.